Cartesian Therapeutics Inc. (RNAC), a clinical-stage biotechnology company, on Tuesday shared positive updates on its Phase 2b trial of Descartes-08, an mRNA therapy for generalized myasthenia gravis.
In the trial, Descartes-08 led to a 5.5-point reduction in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score by Month 4.
This improvement continued through Month 12, with 80 percent of participants maintaining a meaningful response.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.